In AML, miR-29 suppression is associated to translocations involving the MLL oncogene (Li et al, 2008), but it is induced in patients with NPM1 mutations in the absence of FLT3-ITD alterations (Garzon et al, 2008). The gene discussed is KMT2A; the disease is acute myeloid leukemia.